EE05519B1 - im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits - Google Patents

im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits

Info

Publication number
EE05519B1
EE05519B1 EEP200000012A EEP200000012A EE05519B1 EE 05519 B1 EE05519 B1 EE 05519B1 EE P200000012 A EEP200000012 A EE P200000012A EE P200000012 A EEP200000012 A EE P200000012A EE 05519 B1 EE05519 B1 EE 05519B1
Authority
EE
Estonia
Prior art keywords
interleukin
immune
receptor
protein
pharmaceutical composition
Prior art date
Application number
EEP200000012A
Other languages
English (en)
Estonian (et)
Inventor
Michel@Revel
Judith@Chebath
Tsvee@Lapidot
Orit@@ollet
Original Assignee
Yeda@Research@and@Development@Co@@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda@Research@and@Development@Co@@Ltd filed Critical Yeda@Research@and@Development@Co@@Ltd
Publication of EE200000012A publication Critical patent/EE200000012A/xx
Publication of EE05519B1 publication Critical patent/EE05519B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000012A 1997-07-10 1998-07-09 im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits EE05519B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
EE200000012A EE200000012A (et) 2000-08-15
EE05519B1 true EE05519B1 (et) 2012-02-15

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000012A EE05519B1 (et) 1997-07-10 1998-07-09 im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits

Country Status (27)

Country Link
US (2) US7198781B1 (pl)
EP (1) EP0991661B1 (pl)
JP (1) JP4402288B2 (pl)
KR (1) KR100505172B1 (pl)
CN (1) CN1185348C (pl)
AR (1) AR013201A1 (pl)
AT (1) ATE342915T1 (pl)
AU (1) AU758161B2 (pl)
BG (1) BG64680B1 (pl)
BR (1) BR9812096B1 (pl)
CA (1) CA2295936C (pl)
CY (1) CY1105895T1 (pl)
CZ (1) CZ302488B6 (pl)
DE (1) DE69836217T2 (pl)
DK (1) DK0991661T3 (pl)
EA (1) EA004793B1 (pl)
EE (1) EE05519B1 (pl)
ES (1) ES2271999T3 (pl)
HK (1) HK1031895A1 (pl)
HU (1) HU225855B1 (pl)
IL (2) IL122818A0 (pl)
NO (1) NO327397B1 (pl)
NZ (1) NZ502139A (pl)
PL (1) PL199212B1 (pl)
PT (1) PT991661E (pl)
SK (1) SK287039B6 (pl)
WO (1) WO1999002552A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
DE69927375T2 (de) * 1998-07-06 2006-06-22 Tosoh Corp., Shinnanyo Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
ATE377076T1 (de) * 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
IL130586A0 (en) 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
US7446183B2 (en) 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
AU9184901A (en) 2000-09-14 2002-03-26 Ares Trading Sa Use of il-6r/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1499332A4 (en) * 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
SG177946A1 (en) 2005-08-29 2012-02-28 Technion Res & Dev Foundation Media for culturing stem cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
EP3441459B1 (en) 2006-08-02 2021-03-17 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
US20110182848A1 (en) * 2007-08-03 2011-07-28 Asterion Limited Granulocyte colony stimulating factor
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
AU2009266856A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc IL6 immunotherapeutics
EP2310508A1 (en) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
ES2932664T3 (es) 2009-11-12 2023-01-23 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en estado no diferenciado
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG10202109393RA (en) 2010-09-07 2021-10-28 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP3033415A4 (en) * 2013-08-12 2017-01-11 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
US20240269236A1 (en) 2021-06-04 2024-08-15 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JP4601163B2 (ja) * 1997-12-19 2010-12-22 メルク・セローノ・ソシエテ・アノニム Ｉｆｎａｒ２／ｉｆｎ複合体

Also Published As

Publication number Publication date
SK62000A3 (en) 2000-07-11
CZ200075A3 (cs) 2000-08-16
KR20010021522A (ko) 2001-03-15
NO20000086D0 (no) 2000-01-07
CY1105895T1 (el) 2011-02-02
ATE342915T1 (de) 2006-11-15
HUP0002426A3 (en) 2003-01-28
JP4402288B2 (ja) 2010-01-20
AU8127198A (en) 1999-02-08
AR013201A1 (es) 2000-12-13
HU225855B1 (en) 2007-11-28
EA004793B1 (ru) 2004-08-26
CN1185348C (zh) 2005-01-19
CZ302488B6 (cs) 2011-06-15
IL133972A (en) 2015-07-30
US7374912B2 (en) 2008-05-20
US7198781B1 (en) 2007-04-03
EA200000109A1 (ru) 2000-08-28
JP2001509371A (ja) 2001-07-24
BR9812096B1 (pt) 2011-09-06
AU758161B2 (en) 2003-03-20
EP0991661B1 (en) 2006-10-18
NZ502139A (en) 2002-03-28
KR100505172B1 (ko) 2005-08-03
PL338002A1 (en) 2000-09-25
PL199212B1 (pl) 2008-08-29
CA2295936A1 (en) 1999-01-21
DE69836217T2 (de) 2007-08-23
WO1999002552A2 (en) 1999-01-21
CN1269835A (zh) 2000-10-11
NO20000086L (no) 2000-03-08
HK1031895A1 (en) 2001-06-29
NO327397B1 (no) 2009-06-22
BG104070A (en) 2000-11-30
DE69836217D1 (de) 2006-11-30
DK0991661T3 (da) 2007-02-05
SK287039B6 (sk) 2009-10-07
PT991661E (pt) 2007-01-31
EP0991661A2 (en) 2000-04-12
BG64680B1 (bg) 2005-11-30
US20070172455A1 (en) 2007-07-26
ES2271999T3 (es) 2007-04-16
CA2295936C (en) 2009-05-26
EE200000012A (et) 2000-08-15
WO1999002552A3 (en) 1999-04-01
IL122818A0 (en) 1998-08-16
BR9812096A (pt) 2000-07-18
HUP0002426A2 (hu) 2000-11-28

Similar Documents

Publication Publication Date Title
EE05519B1 (et) im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits
PL314051A1 (en) Recombined obesity proteins (ob), fusion proteins, expression vectors, sequential dnas, transformed e, collie cells, method of obtaining recombined human or mouse's obesity protein and pharmaceutic composition
EP1225225A3 (en) Osteogenic devices
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
HUP0002831A3 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
ATE327254T1 (de) Interferon-beta fusionsproteine und deren verwendungen
MX9502034A (es) Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion.
GB9720054D0 (en) Biological products
HK1023071A1 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparing same
ES2181281T3 (es) Formulaciones liquidas de interferon beta.
HU9601908D0 (en) T cell antigen receptor v region proteins and methods of preparation thereof
EP0927270A4 (en) PRESERVATION OF DNA AND RNA BY LYOPHILIZATION OF CULTIVATED HUMAN CELLS
WO1997031934A3 (de) Neue metabolisierbare lipopolyamine, deren darstellung und anwendung
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
BR9604938A (pt) Vírus recombinante deficiente utilização deste vírus composição farmacêutica e célula de mamífero
NO20000990L (no) Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>
DK292584A (da) Biologisk aktive konjugater, deres fremstilling og anvendelse
HK1017378A1 (en) Processes for preparation of marek's disease virus using continuous mammalian cell lines
DE3782350D1 (de) Rekombinante parvovirus-ra-1-produkte und verfahren zu deren anwendung.
DK1084246T3 (da) Biologisk materiale til fremstilling af farmaceutiske præparater til behandling af pattedyr
太田誠志 Hyaluronate activates tyrosine phosphorylation of cellular proteins including focal adhesion kinase via CD44 in human glioma cells
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
GB8617594D0 (en) Preparation of biologically active proteins

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20160709